Armata Pharmaceuticals, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Deborah L. Birx
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4503 Glencoe Avenue Los Angeles CA United States of America 90066
- IPO Date
- May 20, 1994
- CIK
- 0000921114
- Website
- armatapharma.com
- Similar Companies
- Business
- Armata Pharmaceuticals, Inc. (ARMP) is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. The company offers a broad pipeline of natural and synthetic phage candidates, including lead products AP-PA02, an inhaled therapy for chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis and bronchiectasis patients; AP-SA02, an intravenous therapy for Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa pneumonia; with additional candidates targeting other pathogens. Founded in 2019 through the merger of AmpliPhi Biosciences Corporation (established 1989) and C3J Therapeutics, Inc., Armata Pharmaceuticals maintains headquarters in Marina del Rey, California, and conducts worldwide operations in the biotech and pharma sectors serving patients with chronic and acute infections. Recent developments include positive topline results from the Phase 1b/2a diSArm trial of AP-SA02 meeting all primary endpoints for safety, tolerability, and clinical response in May 2025; a $15 million secured credit agreement with Innoviva Strategic Opportunities LLC maturing in 2029 announced in August 2025 to advance lead programs; and $4.65 million in additional non-dilutive funding from the U.S. Department of Defense in early 2025 to support the diSArm trial, alongside plans for a Phase 3 pivotal study in 2026.
Company News
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus